Screener
Corvus Pharmaceuticals CRVS Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Corvus Pharmaceuticals’s reported figures.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
FAQ
- What is Corvus Pharmaceuticals's enterprise value?
- Corvus Pharmaceuticals (CRVS) reported enterprise value of $1.19B in Q1 2026.
- How has Corvus Pharmaceuticals's enterprise value changed year-over-year?
- Corvus Pharmaceuticals's enterprise value increased by 458.9% year-over-year, from $212.83M to $1.19B.
- What is the long-term trend for Corvus Pharmaceuticals's enterprise value?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's enterprise value has grown at a 30.4% compound annual growth rate (CAGR), from $151.57M to $571.41M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Corvus Pharmaceuticals's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude